Genomics Limited: Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First-in-Class Treatments for Autoimmune Diseases

ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases.Genomics will assemble the largest available genetic resource to evaluate how ERAP variants ...

Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases

Genomics, a science-led techbio company using large-scale genetic information to accelerate drug discovery and development and develop innovative precision healthcare tools, today announced a ...

The gutting of the NIH and the capitalist assault on public health

The dismantling of public health through NIH funding cuts, CDC censorship and Medicaid rollbacks is a deliberate attack on ...

Onco3R Therapeutics BV: Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline

Financing led by Sofinnova Investments and co-led by Forbion and Novo Holdings Proceeds to advance lead immunology program COL-5671, a potential first-in-class, oral once-daily therapy, across a range ...
The Manila Times

Coave Therapeutics to unveil OneAAVTM universal capsid at ASGCT 2026, paving the way for third generation gene therapy vectors

Conjugation of universal, functionally de-targeted OneAAVTM capsid provides on-demand specificity and scalabilityto address ...

Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline

Financing led by Sofinnova Investments and co-led by Forbion and Novo HoldingsProceeds to advance lead immunology program COL-5671, a potential ...

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class …

Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris’ Target Profile, ...